B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Canertinib Dihydrochloride

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Canertinib Dihydrochloride, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

ac
3 shared targets
hematoxylin
4 shared targets
dacomitinib
4 shared targets
lapatinib
2 shared targets
falnidamol
2 shared targets
erlotinib
2 shared targets
bdb
2 shared targets
bdb
2 shared targets
bdb
2 shared targets
bdb
2 shared targets
Loading evidence profile...

This evidence profile for Canertinib Dihydrochloride is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.